Skip to main content

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting · Phase 1 · NCT04521686

Conditions: Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor

At a glance

Research payments reported, 2025
$147,448
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
200

About the trial

Sponsor
Eli Lilly and Company
Tested
LY3410738 (drug), Gemcitabine (drug), Cisplatin (drug), Durvalumab (drug)
Dates
Started 2020-10-01; completion 2027-05
Results posted
Not yet

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.

From ClinicalTrials.gov, last updated 2026-07-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $147,448 in research payments for this study in 2025 (4 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $115,940
  • Univ of Arizona DBA Arizona Board of Regents $16,682
  • South Texas Accelerated Research Therapeutics LLC $7,885
  • Johns Hopkins University $6,941

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.